The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Research works printed but not linked: 1
- Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
Cited by
Sorted by citations
Items 401–500 of 1,000
A DDX31/Mutant–p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer
Daizumoto, K., Yoshimaru, T., Matsushita, Y., Fukawa, T., Uehara, H., Ono, M., Komatsu, M., Kanayama, H., & Katagiri, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2528 · Cited by 34
Dudek, A. M., van Kampen, J. G. M., Witjes, J. A., Kiemeney, L. A. L. M., & Verhaegh, G. W. C. T. (2018) · Cancer Medicine · doi:10.1002/cam4.1570 · Cited by 36
Monteiro, L. L., Witjes, J. A., Agarwal, P. K., Anderson, C. B., Bivalacqua, T. J., Bochner, B. H., Boormans, J. L., Chang, S. S., Dominguez-Escrig, J. L., McKiernan, J. M., et al. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2438-9 · Cited by 36
Chen, Y., Peng, Y., Xu, Z., Ge, B., Xiang, X., Zhang, T., Gao, L., Shi, H., Wang, C., & Huang, J. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.11.015 · Cited by 36
Paillas, S., Then, C. K., Kilgas, S., Ruan, J.-L., Thompson, J. M., Elliott, A., Smart, S., & Kiltie, A. E. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.015 · Cited by 36
Matuszczak, M., & Salagierski, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093360 · Cited by 36
Shou, J., Zhang, Q., & Zhang, D. (2021) · World Journal of Urology · doi:10.1007/s00345-021-03721-6 · Cited by 36
Fanale, D., Corsini, L. R., Scalia, R., Brando, C., Cucinella, A., Madonia, G., Dimino, A., Filorizzo, C., Barraco, N., Bono, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103597 · Cited by 37
Yan, H., Xie, H., Ying, Y., Li, J., Wang, X., Xu, X., & Zheng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s164840 · Cited by 37
Li, W., Wang, Y., Tan, S., Rao, Q., Zhu, T., Huang, G. C., Li, Z. Y., & Liu, G. (2018) · Medical Science Monitor · doi:10.12659/msm.911640 · Cited by 35
MicroRNA‑154 functions as a tumor suppressor in bladder cancer by directly targeting ATG7
Zhang, J., Mao, S., Wang, L., Zhang, W., Zhang, Z., Guo, Y., Wu, Y., Yi, F., & Yao, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6879 · Cited by 35
High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer
Shi, M., Meng, X., Wu, Q., & Zhou, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s191105 · Cited by 35
New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer
Alban, L., Monteiro, W. F., Diz, F. M., Miranda, G. M., Scheid, C. M., Zotti, E. R., Morrone, F. B., & Ligabue, R. A. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.110662 · Cited by 35
Circular RNA CircHIPK3 Promotes Gemcitabine Sensitivity in Bladder Cancer
Xie, F., Zhao, N., Zhang, H., & Xie, D. (2020) · Journal of Cancer · doi:10.7150/jca.39722 · Cited by 36
Li, R., Li, Y., Song, J., Gao, K., Chen, K., Yang, X., Ding, Y., Ma, X., Wang, Y., Li, W., et al. (2020) · BMC Urology · doi:10.1186/s12894-020-00610-9 · Cited by 35
Kang, W., Wang, Q., Dai, Y., Wang, H., Wang, M., Wang, J., Zhang, D., Sun, P., Qi, T., Jin, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03240-z · Cited by 35
Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review
Wolfs, J. R. E., Hermans, T. J. N., Koldewijn, E. L., & van de Kerkhof, D. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.11.014 · Cited by 35
Yu, E. Y.-W., Wesselius, A., Mehrkanoon, S., Goosens, M., Brinkman, M. T., van den Brandt, P. A., Grant, E. J., White, E., Weiderpass, E., Calvez‐Kelm, F. L., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-01931-8 · Cited by 35
Li, P., Mi, Q., Yan, S., Xie, Y., Cui, Z., Zhang, S., Wang, Y., Gao, H., Wang, Y., Li, J., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05598-2 · Cited by 35
Khetrapal, P., Lee, M. W. L., Tan, W. S., Dong, L., de Winter, P., Feber, A., & Kelly, J. D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.03.007 · Cited by 36
Zhuo, Z., Song, Z., Ma, Z., Zhang, Y., Xu, G., & Chen, G. (2019) · Oncology Reports · doi:10.3892/or.2019.7013 · Cited by 35
RAB14 activates MAPK signaling to promote bladder tumorigenesis
Chao, H., Deng, L., Xu, F., Fu, B., Zhu, Z., Dong, Z., Liu, Y., & Zeng, T. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz039 · Cited by 34
Tyagi, A., Chandrasekaran, B., Kolluru, V., Rai, S., Jordan, A. C., Alatassi, H., Messer, J. C., Ankem, M. K., Damodaran, C., & Haddad, A. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.03.008 · Cited by 34
Almeida, T. C., Guerra, C. C. C., Assis, B. L. G. D., Aguiar‐Soares, R. D. D. O., Garcia, C. C. M., Lima, A. A., & da Silva, G. N. (2019) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22297 · Cited by 34
Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression
Matarazzo, S., Melocchi, L., Rezzola, S., Grillo, E., Maccarinelli, F., Giacomini, A., Turati, M., Taranto, S., Zammataro, L. A., Cerasuolo, M., et al. (2019) · Cancers · doi:10.3390/cancers11091277 · Cited by 33
Ma, W., Zhang, W., Shen, L., Liu, J., Yang, F., Maskey, N., Wang, H., Zhang, J. J., Yan, Y., & Yao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.677605 · Cited by 34
Socio-economic burden of disease: Survivorship costs for bladder cancer
Michaeli, J. C., Boch, T., Albers, S., Michaeli, T., & Michaeli, D. T. (2022) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2022.100326 · Cited by 36
Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes
Zhao, H., Chen, Z., Fang, Y., Su, M., Xu, Y., Wang, Z., Gyamfi, M. A., & Zhao, J. (2022) · Journal of Immunology Research · doi:10.1155/2022/1793005 · Cited by 37
Shi, Y., Xia, W., Liu, H., Liu, J., Cao, S., Fang, X., Li, S., Li, Y., Chen, C., & Xu, S. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.133760 · Cited by 35
Su, X., Tao, Y., Chen, F., Han, X., & Li, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-92033-5 · Cited by 33
Prospects and progress of immunotherapy for bladder cancer
Boegemann, M., Aydın, A. M., Bagrodia, A., & Krabbe, L. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1366445 · Cited by 33
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer
Dufour, F., Silina, L., Neyret‐Kahn, H., Moreno-Vega, A. I., Krucker, C., Karboul, N., Dorland‐Galliot, M., Maillé, P., Chapeaublanc, E., Allory, Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0397-6 · Cited by 33
Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
Einstein, D. J., & Sonpavde, G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0609-6 · Cited by 33
The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer
Zhang, X., Liu, X., Jing, Z., Bi, J., Li, Z., Liu, X., Li, J., Li, Z., Zhang, Z., & Kong, C. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0085-y · Cited by 33
Erdafitinib for the treatment of urothelial cancer
Marandino, L., Raggi, D., Giannatempo, P., Farè, E., & Necchi, A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1671190 · Cited by 33
Tsui, K., Lin, Y., Chang, K., Hou, C., Chen, P.-J., Feng, T., & Juang, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194946 · Cited by 33
Schmid, S. C., Koll, F. J., Rödel, C. M., Maisch, P., Sauter, A. P., Beckert, F., Seitz, A. K., Kübler, H. R., Flentje, M. P., Chun, F. K. ‐., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6503-6 · Cited by 33
Chandrashekar, D. S., Chakravarthi, B. V. S. K., Robinson, A. D., Anderson, J. C., Agarwal, S., Balasubramanya, S. A. H., Eich, M., Bajpai, A. K., Davuluri, S., Guru, M. S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1275-7 · Cited by 34
Shi, Y.-R., Wu, Z., Xiong, K., Liao, Q., Xu, Y., Yang, P., & Zu, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00605 · Cited by 33
Mao, S., Wu, Y., Wang, R., Guo, Y., Bi, D., Ma, W., Zhang, W., Zhang, J., Yan, Y., & Yao, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s237174 · Cited by 33
Dianatinasab, M., Wesselius, A., Salehi‐Abargouei, A., Yu, E. Y.-W., Brinkman, M. T., Fararouei, M., van den Brandt, P. A., White, E., Weiderpass, E., Calvez‐Kelm, F. L., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33173 · Cited by 32
Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer
Chen, X., Jin, Y., Gong, L., He, D., Cheng, Y., Xiao, M., Zhu, Y., Wang, Z., & Cao, K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00607 · Cited by 32
He, H., Wu, S., Ai, K., Xu, R., Zhong, Z., Wang, Y., Zhang, L., Zhao, X., & Zhu, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00563-z · Cited by 33
Tratnjek, L., Jeruc, J., Romih, R., & Zupančič, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073510 · Cited by 33
Approaches to Non-Muscle-Invasive Bladder Cancer
Slovacek, H., Zhuo, J., & Taylor, J. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01091-1 · Cited by 33
Zhou, X., Wang, F., Wu, H., Chen, X., Zhang, Y., Lin, J., Cai, Y., Xiang, J., He, N., Hu, Z., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60401 · Cited by 33
Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy
Taniyama, D., Sakamoto, N., Takashima, T., Takeda, M., Phạm, Q. T., Ukai, S., Maruyama, R., Harada, K., Babasaki, T., Sekino, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.15207 · Cited by 34
Qiu, Y., Gao, Y., Chen, C., Xie, M., Huang, P., Sun, Q., Zhou, Z., Li, B., Zhao, J., & Wu, P. (2022) · Human Cell · doi:10.1007/s13577-021-00659-0 · Cited by 34
Du, D., He, J., Ju, C., Wang, C., Li, H., He, F., & Zhou, M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216165 · Cited by 33
Diagnostic potential of major and trace elements in the serum of bladder cancer patients
Wach, S., Weigelt, K., Michalke, B., Lieb, V., Stoehr, R., Keck, B., Hartmann, A., Wullich, B., Taubert, H. W., & Chaudhri, A. (2017) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2017.12.010 · Cited by 32
Circular RNAs Serve as Novel Biomarkers and Therapeutic Targets in Cancers
Fang, S., Pan, J., Zhou, C., Tian, H., He, J., Shen, W., Jin, X., Meng, X., Jiang, N., & Gong, Z. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181109142756 · Cited by 32
Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer
Mandelli, G. E., Missale, F., Bresciani, D., Gatta, L. B., Scapini, P., Caveggion, E., Roca, E., Bugatti, M., Monti, M., Cristinelli, L., et al. (2020) · Cells · doi:10.3390/cells9020291 · Cited by 32
miR‑21 inhibits autophagy and promotes malignant development in the bladder cancer T24�cell line
Zhang, H., Huang, Z., Zhong, S., Fei, K., & Cao, Y. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4984 · Cited by 32
DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1
Lai, C., Xu, K., Zhou, J., Wang, M., Zhang, W., Liu, X., Xiong, J., Wang, T., Wang, Q., Wang, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03190-6 · Cited by 32
Circular RNA Foxo3: A Promising Cancer-Associated Biomarker
Yang, T., Yang, L., Zhao, F., Zhou, L., & Jia, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.652995 · Cited by 34
MD-UNET: Multi-input dilated U-shape neural network for segmentation of bladder cancer
Ge, R., Cai, H., Yuan, X., Qin, F., Huang, Y., Wang, P., & Lyu, L. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107510 · Cited by 32
Wang, F., Zhang, Y., Zhou, X., Chen, X., Xiang, J., Fan, M., Yu, Y., Cai, Y., Wu, H., Huang, S., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.704683 · Cited by 31
Wu, Q., Chen, P., Li, J., Lin, Z., Zhang, Q., & Kwok, H. F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106654 · Cited by 32
Changes in male sexuality after urologic cancer: a narrative review
Barros, R. D. C., Favorito, L. A., Nahar, B., Almeida, R., Jr., & Ramasamy, R. (2023) · International braz j urol · doi:10.1590/s1677-5538.ibju.2023.9901 · Cited by 31
Tang, Q., Zuo, W., Wan, C., Xiong, S., Xu, C., Yuan, C., Sun, Q., Zhou, L., & Li, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1097730 · Cited by 31
Hashemi, M., Esbati, N., Rashidi, M., Gholami, S., Raesi, R., Bidoki, S. S., Goharrizi, M. A. S. B., Motlagh, Y. S. M., Khorrami, R., Tavakolpournegari, A., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101846 · Cited by 31
Hu, R., Zhong, P., Xiong, L., & Duan, L. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3785 · Cited by 31
Pulido, M., Roubaud, G., Cazeau, A. L., Mahammedi, H., Védrine, L., Joly, F., Mourey, L., Pfister, C., Goberna, A., Lortal, B., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4059-5 · Cited by 31
Inherited Forms of Bladder Cancer: A Review of Lynch Syndrome and Other Inherited Conditions
Phelan, A., Antonio Lopez-beltran, B., Montironi, R., Zhang, S., Raspollini, M. R., Cheng, M., Kaimakliotis, H. Z., Koch, M. O., & Liang Cheng, C. (2018) · Future Oncology · doi:10.2217/fon-2017-0346 · Cited by 31
van Osch, F., Jochems, S. H. J., Reulen, R. C., Pirrie, S. J., Nekeman, D., Wesselius, A., James, N. D., Wallace, D. M. A., Cheng, K. K., van Schooten, F., et al. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1046-8 · Cited by 31
Ali, A., Song, Y. P., Mehta, S., Mistry, H. B., Conroy, R., Coyle, C., Logue, J. P., Tran, A. T. H., Wylie, J. P., Janjua, T., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.06.2541 · Cited by 31
Tan, L., Xiao, K., Ye, Y., Liang, H., Chen, M., Luo, J., & Qin, Z. (2020) · Aging · doi:10.18632/aging.103198 · Cited by 32
Yoshino, H., Enokida, H., Osako, Y., Nohata, N., Yonemori, M., Sugita, S., Kuroshima, K., Tsuruda, M., Tatarano, S., & Nakagawa, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12697 · Cited by 32
Eckstein, M., Epple, E., Jung, R., Weigelt, K., Lieb, V., Sikic, D., Stöhr, R., Geppert, C. I., Weyerer, V., Bertz, S., et al. (2020) · Cancers · doi:10.3390/cancers12051253 · Cited by 31
Zvereva, M. I., Pisarev, E., Hosen, M. I., Валерьевна, К. О., Мацкеплишвили, С. Т., Kubareva, E. A., Kamalov, D. M., Tivtikyan, A. S., Manel, A., Vian, E., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176034 · Cited by 35
Bi, H., Shang, Z., Jia, C., Wu, J., Cui, B., Wang, Q., & Ou, T. (2020) · Cancer Management and Research · doi:10.2147/cmar.s259117 · Cited by 32
Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex
Brisuda, A., Ho, J. C. S., Kandiyal, P. S., Ng, J. T. Y., Ambite, I., Butler, D. S. C., Háček, J., Wan, M. L. Y., Tran, T. H., Nadeem, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23748-y · Cited by 33
Xiang, Z., Ye, Z., Ma, J., Lin, Y., & Zhou, Y. (2022) · Clinical Epidemiology · doi:10.2147/clep.s387289 · Cited by 31
Cani, M., Turco, F., Butticè, S., Vogl, U. M., Buttigliero, C., Novello, S., & Capelletto, E. (2023) · Cancers · doi:10.3390/cancers15102836 · Cited by 40
He, X., Ping, J., & Wen, D.-G. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4908 · Cited by 30
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review
Lotan, Y., Black, P. C., Caba, L., Chang, S. S., Cookson, M. S., Daneshmand, S., Kamat, A. M., McKiernan, J. M., Pruthi, R. S., Ritch, C. R., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.04.010 · Cited by 30
Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis
Yang, Y., Cheng, Z., Jia, X., Shi, N., Xia, Z., Zhang, W., & Shi, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189220 · Cited by 30
Li, B., Xie, D., & Zhang, H. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03873-8 · Cited by 30
Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion
Xin, F., Yao, D.-W., Li, F., Jiu-hua, L., & Liu, X. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00576-5 · Cited by 30
Nomogram for predicting overall survival of patients with bladder cancer: A population-based study
Wang, J., Wu, X., He, W., Yang, B., & Gou, X. (2020) · The International Journal of Biological Markers · doi:10.1177/1724600820907605 · Cited by 30
Alternative splicing related genetic variants contribute to bladder cancer risk
Guo, Z., Zhu, H., Xu, W., Wang, X., Liu, H., Wu, Y., Wang, M., Chu, H., & Zhang, Z. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23207 · Cited by 30
Liu, B., Zhan, Y., Chen, X., Hu, X., Wu, B., & Pan, S. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29939 · Cited by 29
Liu, B., Pan, S., Liu, J., & Kong, C. (2021) · Gene · doi:10.1016/j.gene.2021.145451 · Cited by 30
Anti-Cancer Effects and Tumor Marker Role of Glutathione S-Transferase Mu 5 in Human Bladder Cancer
Jou, Y., Wang, S., Dia, Y.-C., Wang, S., Yu, M., Yang, H., Chen, L.-C., Shen, C., & Liu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063056 · Cited by 30
Chen, D., Xie, S., Wu, Y., Cui, Y., Cai, Y., Lan, L., Yang, H., Chen, J., & Chen, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.572672 · Cited by 29
Detecting Muscle Invasion of Bladder Cancer Using a Proposed Magnetic Resonance Imaging Strategy
Wang, X., Tu, N., Sun, F., Wen, Z., Lan, X., Yi, L., Cui, E., & Lin, F. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27676 · Cited by 30
Biological Functions and Prognostic Value of Ferroptosis-Related Genes in Bladder Cancer
Yi, K., Liu, J., Rong, Y., Wang, C., Tang, X., Zhang, X., Xiong, Y., & Wang, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.631152 · Cited by 30
Wang, X., Zhang, S., Jin, D., Luo, J., Shi, Y., Zhang, Y., Wu, L., Song, Y., Su, D., Pan, Z., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12408 · Cited by 30
Phillips, R. M., Hendriks, H. R., Sweeney, J. B., Reddy, G., & Peters, G. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1341490 · Cited by 30
Increased Surgical Complications in Smokers Undergoing Radical Cystectomy
Sathianathen, N. J., Weight, C., Jarosek, S. L., & Konety, B. R. (2018) · Bladder Cancer · doi:10.3233/blc-180185 · Cited by 30
Yan, H., Li, J., Ying, Y., Xie, H., Chen, H., Xu, X., & Zheng, X. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1557490 · Cited by 30
JAM3: A prognostic biomarker for bladder cancer via epithelial–mesenchymal transition regulation
Pang, Z.-Q., Wang, J., Wang, J., Wang, Y., Ji, B., Xu, Y.-D., He, J., Zhang, L., Zhang, L.-Q., Ding, B.-C., et al. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2024.9979 · Cited by 29
Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder cancer
Zhu, Q., Zhang, G., Cao, M., Huang, H., He, D., Zang, Z., Xing, J., Zhan, M., Pei, S., Deng, X., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02126-6 · Cited by 30
YRNA expression predicts survival in bladder cancer patients
Tolkach, Y., Stahl, A. F., Niehoff, E.-M., Zhao, C., Kristiansen, G., Müller, S. C., & Ellinger, J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3746-y · Cited by 29
Matsumoto, A., Nakagawa, T., Kanatani, A., Ikeda, M., Kawai, T., Miyakawa, J., Taguchi, S., Naito, A., Otsuka, M., Nakanishi, Y., et al. (2017) · World Journal of Urology · doi:10.1007/s00345-017-2141-2 · Cited by 29
The effect of marital status on the survival of patients with bladder urothelial carcinoma
Niu, Q., Lu, Y., Wu, Y., Xu, S., Shi, Q., Huang, T.-B., Zhou, G., Gu, X., & Yu, J. (2018) · Medicine · doi:10.1097/md.0000000000011378 · Cited by 29
OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells
Wang, D., Chen, Z., Lin, F., Wang, Z., Gao, Q., Xie, H., Xiao, H., Zhou, Y., Zhang, F., Ma, Y., et al. (2018) · Journal of Cancer · doi:10.7150/jca.27381 · Cited by 29
NIMA related kinase 2 promotes gastric cancer cell proliferationviaERK/MAPK signaling
Fan, W., Chen, T., & Liu, P.-J. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2898 · Cited by 29
Acham, M., Wesselius, A., van Osch, F., Yu, E. Y.-W., van den Brandt, P. A., White, E., Adami, H., Weiderpass, E., Brinkman, M. T., Giles, G. G., et al. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-019-0453-6 · Cited by 29
Tsai, Y.-S., Jou, Y., Tsai, H.-T., Cheong, I.-S., & Tzai, T. (2019) · Urologic oncology · doi:10.1016/j.urolonc.2019.05.005 · Cited by 19
Metadata
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
